Gene therapy of prostate cancer: Current and future directions

Endocrine-Related Cancer

Volumn 9, Issue 2, 2002, Pages 115-139

  Mabjeesh, N J ^a   Zhong, H ^a   Simons, Jonathan W ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CELL ADHESION MOLECULE; DIPHTHERIA TOXIN; DNA FRAGMENT; DNA VACCINE; DOCETAXEL; ESTRAMUSTINE; GANCICLOVIR; GENE PRODUCT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; LIPOSOME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MITOXANTRONE; PLASMID DNA; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PSEUDOMONAS EXOTOXIN; RECOMBINANT DNA; RNA; THYMIDINE KINASE; TISSUE KALLIKREIN; TUMOR CELL VACCINE; VACCINE; VIRUS VECTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL TRIAL; DNA PROTEIN COMPLEX; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; HERPES VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOTHERAPY; LENTIVIRINAE; MALE; NONHUMAN; ONCOGENE; PROSTATE CANCER; SPUMA VIRUS; TUMOR SUPPRESSOR GENE; VACCINIA VIRUS;

FORECASTING; GENE THERAPY; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 0036324470     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0090115     Document Type: Article

References (162)

1. Radiogenetic therapy: On the interaction of viral therapy and ionizing radiation for improving local control of tumors
2. Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: A new paradigm for destruction of therapeutically intractable tumors
3. Dual expression of human leukocyte antigen molecules and the B7-1 costimulatory molecule (CD80) on human melanoma cells after particle-mediated gene transfer
4. Human gene therapy
5. Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector
6. Dendritic cells and the control of immunity
7. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules
8. Molecular correlates of bcl-2-enhanced growth following androgen-ablation in prostate carcinoma cells in vivo
9. DNA vaccine strategies for the treatment of cancer
10. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
11. Loss of HLA class I expression in prostate cancer: Implications for immunotherapy
12. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo
13. p53 is mutated in a subset of advanced-stage prostate cancers
14. Adenovirus E1A expression enhances the sensitivity of an ovarian cancer cell line to multiple cytotoxic agents through an apoptotic mechanism
15. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases
16. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine
17. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy
18. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells
19. The role of beta-catenin in cell adhesion, signal transduction, and cancer
20. Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers
21. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells
22. Origin, maturation and antigen presenting function of dendritic cells
23. Enhanced therapeutic effect of hsv-tk+gcv gene therapy and ionizing radiation for prostate cancer
24. Frequent alteration of CDKN2 (p16(INK4A)/MTS1) expression in human primary prostate carcinomas
25. Functional complementation of the adenovirus E1B 19-kilodalton protein with Bcl-2 in the inhibition of apoptosis in infected cells
26. Prostate cancer: Screening and early detection
27. Amphotropic murine leukemia retrovirus is not an acute pathogen for primates
28. High-efficiency receptor-mediated delivery of small and large (48 kilobase) gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles
29. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
30. Hepatic gene therapy: Efficient gene delivery and expression in primary hepatocytes utilizing a conjugated adenovirus-DNA complex
31. Viral and nonviral gene delivery vectors for cancer gene therapy
32. Activation of the androgen receptor by polypeptide growth factors and cellular regulators
33. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor
34. Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: A decade of progress?
35. High-efficiency gene transfer employing adenovirus-polylysine-DNA complexes
36. Hypoxia modulated gene expression: Angiogenesis, metastasis and therapeutic exploitation
37. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression
38. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B
39. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy
40. KAII, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2
41. Development of a hammerhead ribozyme against bcl-2. I. Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer
42. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
43. Chromosome 5 suppresses tumorigenicity of PC3 prostate cancer cells: Correlation with re-expression of alpha-catenin and restoration of E-cadherin function
44. Giving DNA vaccines a helping hand
45. Oncogene-dependent apoptosis is mediated by caspase-9
46. Adenovirus dodecahedron, a new vector for human gene transfer
47. Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia
48. Adenovirus-mediated transfection of cultured cells
49. A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy
50. Expression of bcl-2 and the progression of human and rodent prostatic cancers
51. Selective in vivo radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells transduced with the E. coli cytosine deaminase (CD) gene
52. Delivery systems intended for in vivo gene therapy of cancer: Targeting and replication competent viral vectors
53. HIV-1 infection of nondividing cells: C-terminal tyrosine phosphorylation of the viral matrix protein is a key regulator
54. HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase
55. Suppression of the tumorigenicity of prostatic cancer cells by gene(s) located on human chromosome 19p13.1-13.2
56. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer
57. Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus
58. Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer
59. Role of gene therapy in radiation oncology
60. A method of limited replication for the efficient in vivo delivery of adenovirus to cancer cells
61. Dose escalation with 3D conformal treatment: Five year outcomes, treatment optimization, and future directions
62. Virally directed cytosine deaminase/5-fluorocytosine gene therapy enhances radiation response in human cancer xenografts
63. Gene therapy for cancer using tumour-specific prodrug activation
64. Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer
65. Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA
66. In situ gene therapy for adenocarcinoma of the prostate: A phase I clinical trial
67. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules
68. Insulin-like growth factor binding protein-3 and -5 are regulated by transforming growth factor-beta and retinoic acid in the human prostate adenocarcinoma cell line PC-3
69. Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis
70. Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo
71. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors
72. Molecular biology of prostate cancer
73. Molecular biology of prostate cancer progression
74. Deletional, mutational, and methylation analyses of CDKN2 (p16/MTSI) in primary and metastatic prostate cancer
75. Cell-type-specific gene transfer into human cells with retroviral vectors that display single-chain antibodies
76. Cell-surface receptors for gibbon ape leukemia virus and amphotropic murine retrovirus are inducible sodium-dependent phosphate symporters
77. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration
78. Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine
79. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma
80. ONYX-015: Clinical data are encouraging
81. Genetic changes in prostate cancer
82. Sustained cytokine delivery for anticancer vaccination: Liposomes as alternative for genetransfected tumor cells
83. Site-specific integration by adeno-associated virus
84. Encapsidated adenovirus mini-chromosome-mediated delivery of genes to the retina: Application to the rescue of photoreceptor degeneration
85. Sterically stabilized liposomes: A hypothesis on the molecular origin of the extended circulation times
86. Prostate-specific antigen promoter driven gene therapy targeting DNA polymerase-alpha and topoisomerase II alpha in prostate cancer
87. Folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer
88. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis
89. Adenovirus-mediated Bax overexpression for the induction of therapeutic apoptosis in prostate cancer
90. Construction of new retroviral producer cells from adenoviral and retroviral vectors
91. Human prostate carcinoma cells as targets for herpes simplex virus thymidine kinase-mediated suicide gene therapy
92. Regulation of androgen-dependent prostatic cancer cell growth: Androgen regulation of CDK2, CDK4, and CKI p16 genes
93. The early region 4 orf4 protein of human adenovirus type 5 induces p53-independent cell death by apoptosis
94. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer
95. Differential susceptibility of primary and established human glioma cells to adenovirus infection: Targeting via the epidermal growth factor receptor achieves fibe receptor-independent gene transfer
96. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection
97. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: A phase I/II clinical trial
98. Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector
99. AAV vectors: Is clinical success on the horizon?
100. Novel strategies and therapeutics for the treatment of prostate carcinoma
101. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease
102. Adenovirus-mediated gene transfer into tumors: Evaluation of direct readministration of an adenoviral vector into subcutaneous tumors of immunocompetent mice
103. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector
104. Organizer induction determines left-right asymmetry in Xenopus
105. Methylation of the 5′ CpG island of the endothelin B receptor gene is common in human prostate cancer
106. An expressed-sequence-tag database of the human prostate: Sequence analysis of 1168 cDNA clones
107. The prostate expression database (PEDB): Status and enhancements in 2000
108. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial
109. The adenovirus E4orf6 protein can promote E1A/E1B-induced focus formation by interfering with p53 tumor suppressor function
110. E1A-induced processing of procaspase-8 can occur independently of FADD and is inhibited by Bcl-2
111. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer
112. Retrovirus-mediated herpes simplex virus thymidine kinase gene transduction renders human thyroid carcinoma cell lines sensitive to ganciclovir and radiation in vitro and in vivo
113. IGFBPs and neoplastic models. New concepts for roles of IGFBPs in regulation of cancer cell growth
114. Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer
115. Nonspecific inflammation inhibits adenovirus-mediated pulmonary gene transfer and expression independent of specific acquired immune responses
116. Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen
117. Gene therapy for prostate cancer at the University of California, Los Angeles: Preliminary results and future directions
118. Vaccinia virus for human gene therapy
119. PTEN/MMAC1/TEP1 involvement in primary prostate cancers
120. Gene transfer: A review of methods and applications
121. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism
122. Enhancement of liposome-mediated gene transfer into vascular tissue by replication deficient adenovirus
123. The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins
124. A cascade of adenovirus early functions is required for expression of adeno-associated virus
125. Aberrant E-cadherin and alpha-catenin expression in prostate cancer: Correlation with patient survival
126. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
127. Identification of diphtheria toxin via screening as a potent cell cycle and p53-independent cytotoxin for human prostate cancer therapeutics
128. The coxsackie virus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F
129. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells
130. The genetic analysis of prostate carcinoma
131. Foamy virus vectors
132. Prostate-specific antigen expression is regulated by an upstream enhancer
133. Prostate-specific amplification of expanded polyglutamine expression: A novel approach for cancer gene therapy
134. Hypoxia, HIF-1, and the pathophysiology of common human diseases
135. Development of a hypoxia-responsive vector for tumor-specific gene therapy
136. Apoptosis by retrovirus-and adenovirus-mediated gene transfer of Fas ligand to glioma cells: Implications for gene therapy
137. Biophysical targeting of adenovirus vectors for gene therapy
138. Ex-vivo gene therapy using cytokine-transduced tumor vaccines: Molecular and clinical pharmacology
139. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer
140. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search
141. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases
142. Gene therapy for prostate cancer: Where are we now?
143. Antisense c-myc retroviral vector suppresses established human prostate cancer
144. Growth inhibition of prostate cancer by an adenovirus expressing a novel tumor suppressor gene, pHyde
145. Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy
146. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues
147. The E3-11.6-kDa adenovirus death protein (ADP) is required for efficient cell death: Characterization of cells infected with adp mutants
148. The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells
149. Double suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but not single gene transfer allows reliable elimination of tumor cells in vivo
150. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer
151. Beta-catenin mutations in human prostate cancer
152. Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes
153. Family history facilitates the early diagnosis of prostate carcinoma
154. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression
155. Targeting adenovirus
156. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment
157. Direct gene transfer into mouse muscle in vivo
158. Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 promoter
159. Evidence for a prostate cancer susceptibility locus on the X chromosome
160. Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs
161. Cationic liposomes in gene delivery
162. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer